Advanced Search
8

Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells.

Bourguignon LY, Peyrollier K, Xia W, Gilad E

J Biol Chem. 2008 Jun 20; 283(25):17635-51

8 Must Read

Gregg B Fields, Torrey Pines Institute for Molecular Studies, FL, USA. F1000 Chemical Biology

14 Jul 2008 | Novel Drug Target

CD44 association with hyaluronan, a Glycosaminoglycan located in the extracellular matrix, has long been linked to the multidrug resistance of certain cancers. This study is the first to mechanistically link hyaluronan binding to CD44 with the efflux of chemotherapeutic agents in breast and ovarian tumor cells.

The authors demonstrate that hyaluronan-CD44 interaction induces Nanog-Stat-3 intracellular signaling pathways, which in turn regulate ankyrin association with P-glycoprotein (MDR1) and promotes multidrug fluxes. MDR1 gene expression is also upregulated by the same signaling pathways.

The hypothesis presented suggests that targeting hyaluronan-CD44 interactions, or the Nanog-Stat-3 signaling pathways, may be a new approach for overcoming multidrug resistance in certain tumors.

Competing interests: None declared

Fields G: "CD44 association with hyaluronan, a Glycosaminoglycan located in the extracellular matrix, has long been linked..." Evaluation of: [Bourguignon LY et al. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem. 2008 Jun 20; 283(25):17635-51; doi: 10.1074/jbc.M800109200]. Faculty of 1000, 14 Jul 2008. F1000.com/1116517#eval572550

Short form
Fields G: 2008. F1000.com/1116517#eval572550

Faculty of 1000 evaluations, dissents and comments for [Bourguignon LY et al. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem. 2008 Jun 20; 283(25):17635-51; doi: 10.1074/jbc.M800109200]. Faculty of 1000, 14 Jul 2008. F1000.com/1116517

Short form
Faculty of 1000: 2008. F1000.com/1116517

Only signed-in users with full subscription access can make comments.
Sign in/get access to leave a comment.

No comments yet.

Hyaluronan (HA) is a major glycosaminoglycan in the extracellular matrix whose expression is tightly linked to multidrug resistance and tumor progression. In this study we investigated HA-induced interaction between CD44 (a HA receptor) and Nanog (an embryonic stem cell transcription factor) in both human breast tumor cells (MCF-7 cells) and human ovarian tumor cells (SK-OV-3.ipl cells). Using a specific primer pair to amplify Nanog by reverse transcriptase-PCR, we detected the expression of Nanog transcript in both tumor cell lines. In addition, our results reveal that HA binding to these tumor cells promotes Nanog protein association with CD44 followed by Nanog activation and the expression of pluripotent stem cell regulators (e.g. Rex1 and Sox2). Nanog also forms a complex with the "signal transducer and activator of transcription protein 3" (Stat-3) in the nucleus leading to Stat-3-specific transcriptional activation and multidrug transporter, MDR1 (P-glycoprotein) gene expression. Furthermore, we observed that HA-CD44 interaction induces ankyrin (a cytoskeletal protein) binding to MDR1 resulting in the efflux of chemotherapeutic drugs (e.g. doxorubicin and paclitaxel (Taxol)) and chemoresistance in these tumor cells. Overexpression of Nanog by transfecting tumor cells with Nanog cDNA stimulates Stat-3 transcriptional activation, MDR1 overexpression, and multidrug resistance. Down regulation of Nanog signaling or ankyrin function (by transfecting tumor cells with Nanog small interfering RNA or ankyrin repeat domain cDNA) not only blocks HA/CD44-mediated tumor cell behaviors but also enhances chemosensitivity. Taken together, these findings suggest that targeting HA/CD44-mediated Nanog-Stat-3 signaling pathways and ankyrin/cytoskeleton function may represent a novel approach to overcome chemotherapy resistance in some breast and ovarian tumor cells displaying stem cell marker properties during tumor progression.

DOI: 10.1074/jbc.M800109200

PMID: 18441325

Export